Cas:4091-91-2 3-chloro-1-phenothiazin-10-ylpropan-1-one manufacturer & supplier

Chemical Name:3-chloro-1-phenothiazin-10-ylpropan-1-one

CAS.NO:4091-91-2

Synonyms:3-Chloro-1-phenothiazin-10-yl-propan-1-one

Molecular Formula:C₁₅H₁₂ClNOS

Molecular Weight:289.78000

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:513.7ºC at 760mmHg

Density:1.343g/cm3

Index of Refraction:1.659

PSA:45.61000

Exact Mass:289.03300

LogP:4.50980

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-Chloro-1-phenothiazin-10-yl-propan-1-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Chloro-1-phenothiazin-10-yl-propan-1-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Chloro-1-phenothiazin-10-yl-propan-1-one Use and application,3-Chloro-1-phenothiazin-10-yl-propan-1-one technical grade,usp/ep/jp grade.

Related News: The Wuhan coronavirus has brought back memories of the 2003 outbreak of the severe acute respiratory syndrome, known as SARS, which infected more than 8,000 people and killed 774. 3-chloro-1-phenothiazin-10-ylpropan-1-one manufacturer Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK. 3-chloro-1-phenothiazin-10-ylpropan-1-one supplier The slowdown of pesticide intermediates has dragged down the growth of industrial business. In the future, the pharmaceutical intermediate business will be the focus of the company’s development. 3-chloro-1-phenothiazin-10-ylpropan-1-one vendor An active pharmaceutical ingredient (API) is a substance, or a mixture of ingredients, combined in the manufacture of a pharmaceutical or drug. 3-chloro-1-phenothiazin-10-ylpropan-1-one factory The slowdown of pesticide intermediates has dragged down the growth of industrial business. In the future, the pharmaceutical intermediate business will be the focus of the company’s development.